Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Submitted: 4 March 2013
Accepted: 17 June 2013
Published: 24 July 2013
Abstract Views: 2438
PDF: 635
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

A. Spadaro, Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma

How to Cite

Spadaro, A., Scarno, A., Carboni, A., Perrotta, F., Catalano, C., Lubrano, E., & Valesini, G. (2013). Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis. Reumatismo, 65(3), 134–137. https://doi.org/10.4081/reumatismo.2013.134